Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641867 | 0.86 | CYP2C19 (0.57) | CYP2C19CYP1A2ALDH1A1MAPTMEN1 | |
| SCHEMBL5160372 | 0.82 | CYP2C19 (0.67) | CYP2C19CYP1A2ALDH1A1MAPTMEN1 | |
| SCHEMBL6932662 | 0.82 | CYP2C19 (0.61) | CYP2C19CYP1A2ALDH1A1MAPTMEN1 | |
| SCHEMBL2441292 | 0.81 | ALDH1A1 (0.57) | CYP2C19CYP1A2ALDH1A1MAPTMEN1 | |
| Water SCHEMBL8902538 | 0.81 | CYP2C19 (0.65) | CYP2C19CYP1A2ALDH1A1MAPTMEN1 | |
| SCHEMBL7693596 | 0.81 | TSHR (0.53) | CYP2C19CYP1A2ALDH1A1MAPTMEN1 | |
| SCHEMBL9698823 | 0.81 | TSHR (0.53) | CYP2C19CYP1A2ALDH1A1MAPTMEN1 | |
| SCHEMBL6659092 | 0.81 | LOXL2 (0.57) | CYP2C19CYP1A2ALDH1A1MAPTMEN1 | |
| Silver SCHEMBL11309103 | 0.80 | CYP2C19 (0.59) | CYP2C19CYP1A2ALDH1A1MAPTMEN1 | |
| SCHEMBL76204 | 0.80 | CYP2C19 (0.64) | CYP2C19CYP1A2ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395894-B2 | BACTERICIDES | MERCK & CO., INC. | 2002-05-28 | — | — | US | claimed |
| US-10933051-B2 | Carbapenem compounds and compositions for the treatment of bacterial infections | FOB SYNTHESIS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200155508-A1 | Carbapenem Compounds and Compositions for the Treatment of Bacterial Infections | CHOI, WOO-BAEG, DR. | 2020-05-21 | — | — | US | disclosed |
| EP-3634471-A1 | CARBAPENEM COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FOB Synthesis, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2018227178-A1 | CARBAPENEM COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FOB SYNTHESIS, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| EP-2127650-B1 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS INC (US) | 2018-12-05 | — | — | EP | disclosed |
| US-9937151-B2 | Carbapenem antibacterials with gram-negative activity | FOB SYNTHESIS, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2590978-B1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY | FOB SYNTHESIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20150306071-A1 | Carbapenem Antibacterials with Gram-Negative Activity | CHOI, WOO-BAEG, DR. | 2015-10-29 | — | — | US | disclosed |
| US-9149461-B2 | Carbapenem antibacterials with gram-negative activity | FOB SYNTHESIS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| EP-0130025-B1 | 2-ALKYLTHIOPENEM DERIVATIVES | PFIZER INC. (US) | 1987-07-08 | — | — | EP | disclosed |
| EP-0211236-A1 | 7-Oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-02-25 | — | — | EP | disclosed |
| US-4619924-A | BACTERICIDES | PFIZER INC. (US) | 1986-10-28 | — | — | US | disclosed |
| US-4614737-A | ANTIBIOTICS | PFIZER INC. (US) | 1986-09-30 | — | — | US | disclosed |
| EP-0167011-A2 | Beta-lactam compounds, intermediates thereof, their use in preparing beta-lactams having a diketopiperazine group | BEECHAM GROUP PLC (GB) | 1986-01-08 | — | — | EP | disclosed |
| EP-0138538-A1 | 2-Dioxacycloalkylthiopenem derivatives | PFIZER INC. (US) | 1985-04-24 | — | — | EP | disclosed |
| EP-0138539-A1 | 2-Azacycloalkylthiopenem derivatives | PFIZER INC. (US) | 1985-04-24 | — | — | EP | disclosed |
| EP-0132101-A1 | 2-Heterocycloalkylthiopenem derivatives | PFIZER INC. (US) | 1985-01-23 | — | — | EP | disclosed |
| EP-0130025-A1 | 2-Alkylthiopenem derivatives | PFIZER INC. (US) | 1985-01-02 | — | — | EP | disclosed |
| US-4395418-A | 6-HYDROXYETHYL SUBSTITUTED ANTIBIOTICS | SANKYO COMPANY LIMITED (JP) | 1983-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10933051-B2 | Carbapenem compounds and compositions for the treatment of bacterial infections | SLC11A2, GSK3B, GSK3A | CYP2C19 895/4885CYP1A2 3090/4885ALDH1A1 3484/4885 |
| US-20200155508-A1 | Carbapenem Compounds and Compositions for the Treatment of Bacterial Infections | SLC11A2, GSK3B, GSK3A | CYP2C19 895/4885CYP1A2 3090/4885ALDH1A1 3484/4885 |
| US-20150306071-A1 | Carbapenem Antibacterials with Gram-Negative Activity | MGAM, GSK3B, GSK3A | CYP2C19 1538/4885CYP1A2 3934/4885ALDH1A1 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.